Progression-free survival
HGG, tumor, MM
DISEASE PROGRESSION, TUMOR
By investigator assessment, the median (95% CI) progression-free survival (PFS) was 6.7 (4.7, 13.8), 9.0 (5.5, 9.4), 9.5, 5.5 (1.8, 13.7) and 6.3 (2.3, 12.9) months in the ATC, BTC, ASI, HGG and MM cohorts, respectively. Due to the small patient numbers, PFS could not be evaluated in the LGG (six patients had disease progression) and HCL (six patients had disease progression and three died) cohorts. By independent radiology assessment, the median (95% CI) PFS was 5.5 (3.7, 12.9), 7.5 (5.4, 12.9), 9.2 (0.9, NR), 9.2 (4.7, 33.0) and 4.5 (1.8, 7.4) months in the ATC, BTC, ASI, LGG and HGG cohorts, respectively. Kaplan–Meier plots for PFS by investigator and independent radiology assessment across tumor cohorts are shown in Extended Data Fig. 